What are the common and serious side effects of Xolair (omalizumab) and how should patients be monitored?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Xolair Side Effects and Monitoring

Most Critical Side Effect: Anaphylaxis

The most serious side effect of Xolair is anaphylaxis, occurring in 0.09-0.2% of patients, with 61% of reactions happening within the first 2 hours after one of the first three doses. 1, 2

Anaphylaxis Risk Timeline

  • Within 30 minutes: 16 documented anaphylactic reactions 2
  • 30-60 minutes: 7 reactions 2
  • 1-2 hours: 5 reactions 2
  • 2-12 hours: 5 delayed reactions including tongue swelling, lingual angioedema, increased asthma symptoms with urticaria, and throat closing sensation 2
  • Beyond 12 hours: 3 reactions documented up to 4 days after administration 2

Mandatory Monitoring Protocol

Patients must be observed for 2 hours after each of the first 3 injections, then 30 minutes after subsequent injections. 3, 1, 2 This captures 75% of anaphylactic reactions. 2

Before each injection, assess:

  • Current health status and recent health changes 3
  • Vital signs 3
  • Lung function (peak expiratory flow or FEV₁) 3

Required Patient Education and Preparation

All patients must:

  • Receive informed consent discussion about anaphylaxis risk 3, 1
  • Be prescribed an epinephrine autoinjector before starting therapy 3, 1
  • Receive training on proper epinephrine autoinjector use 3
  • Carry the epinephrine autoinjector for 24 hours following each injection 2
  • Understand that reactions can occur up to 4 days after administration 2

Common Side Effects

In Adults and Adolescents ≥12 Years with Asthma:

  • Joint pain (especially arms and legs) 4
  • Dizziness 4
  • Fatigue 4
  • Itching and skin rash 4
  • Bone fractures 4
  • Ear pain or discomfort 4
  • Injection site reactions 5, 6
  • Viral infections 5, 6
  • Upper respiratory tract infection 5, 6
  • Sinusitis 5, 6
  • Headache 5, 6
  • Pharyngitis 5, 6

In Children 6 to <12 Years with Asthma:

  • Swelling of nose, throat, or sinuses 4
  • Headache 4
  • Fever 4
  • Throat infection 4
  • Ear infection 4
  • Abdominal pain 4
  • Stomach infection 4
  • Nosebleeds 4

In Adults with Chronic Rhinosinusitis with Nasal Polyps:

  • Headache 4
  • Injection site reactions 4
  • Joint pain 4
  • Upper abdominal pain 4
  • Dizziness 4

In Chronic Spontaneous Urticaria:

  • Nausea 4
  • Headaches 4
  • Swelling of nose, throat, or sinuses 4
  • Cough 4
  • Joint pain 4
  • Upper respiratory tract infection 4

In Food Allergy:

  • Injection site reactions 4
  • Fever 4

Important note: The incidence of adverse events with omalizumab was similar to placebo in clinical trials. 5, 6, 7

Serious but Rare Side Effects

Cancer Risk

Cases of cancer have been observed in patients receiving Xolair, though causality is not established. 4

Blood Vessel Inflammation (Vasculitis)

  • Occurs rarely, usually in asthma patients also taking oral steroids that are being stopped or dose-reduced 4
  • Causality with Xolair is uncertain 4

Immediate symptoms requiring medical attention:

  • Rash 4
  • Shortness of breath 4
  • Chest pain 4
  • Pins and needles or numbness in arms or legs 4

Serum Sickness-Like Reaction

  • Fever, muscle aches, and rash occurring 1-5 days after injection 4

Parasitic Infections

Patients at high risk for parasitic (worm) infections may develop these after receiving Xolair. 4 Stool testing can identify parasitic infections. 4

Cardiovascular Events

Some patients have experienced chest pain, heart attack, blood clots in lungs or legs, or transient stroke-like symptoms (weakness on one side, slurred speech, altered vision), though causality with Xolair is not established. 4

Critical Pitfalls to Avoid

  • Never use Xolair for emergency treatment of allergic reactions, anaphylaxis, hives, or sudden breathing problems. 4
  • Do not reduce or stop other asthma, chronic rhinosinusitis with nasal polyps, hives, food allergy medications, or allergen immunotherapy without provider guidance. 4
  • Do not assume patients are safe after the observation period—educate them about delayed reactions up to 4 days later. 2
  • Do not skip the 2-hour observation for the first 3 doses—this is when most severe reactions occur. 1, 2

References

Guideline

Xolair Therapy Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Anaphylaxis Risk Following Xolair Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Omalizumab: a review of its use in the management of allergic asthma.

Treatments in respiratory medicine, 2004

Research

Spotlight on omalizumab in allergic asthma.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.